DGIdb - FGFR3 Gene Record

FGFR3 2261 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

2261
FIBROBLAST GROWTH FACTOR RECEPTOR 3
FGFR3
ACH
CD333
CEK2
HSFGFR3EX
JTK4
134934
3690
ENSG00000068078
OTTHUMG00000121148
CD_antigen=CD333
FGFR-3
BE0002133
P22607
FGFR3_HUMAN
FIBROBLAST GROWTH FACTOR RECEPTOR 3 PRECURSOR (EC 2.7.1.112) (FGFR-3). [SOURCE:UNIPROT/SWISSPROT;ACC:P22607]
FGFR1-3
1810
23
NP_000133
NM_000142
PA28129
T91331

Gene Info:

Uniprot Evidence	1: Evidence at protein level
Interpro Acc	IPR001245
Interpro Name	Serine-threonine/tyrosine-protein kinase catalytic domain
Interpro Short Name	Ser-Thr/Tyr_kinase_cat_dom
Uniprot Status	Swiss-Prot
Interpro Type	Domain
Human Readable Name	KINASE
Human Readable Name	DRUGGABLE GENOME
CancerCommons Reported Gene Name	FGFRs
CancerCommons Reported Gene Name	FGFR3 and others (VEGFR)
Target Class	Receptors
Target Subclass	EC:2.7.10.1
Target Main Class	Receptors
Target Subclass	Kinase
Target Subclass	FGFR
Transmembrane Helix Count	1
GuideToPharmacology Gene Category Name	Type V RTKs: FGF (fibroblast growth factor) receptor family
GuideToPharmacology Gene Category ID	323
Gene Biotype	PROTEIN_CODING

(27 More Sources)

Gene Categories: Category Details

CELL SURFACE
KINASE
TYROSINE KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.
Williams et al., 2013, Oncogenic FGFR3 gene fusions in bladder cancer., Hum. Mol. Genet.
Hänze et al., 2013, Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells., BMC Cancer
Hahn et al., 2017, A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157., Clin. Cancer Res.
Goyal et al., 2017, Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma., Cancer Discov
Lamont et al., 2011, Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo., Br. J. Cancer
Nakanishi et al., 2015, Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1., Mol. Cancer Ther.
Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet
Yamanaka et al., 2000, Isolation and serum-free culture of epithelial cells derived from epithelial rests of Malassez in human periodontal ligament., In Vitro Cell. Dev. Biol. Anim.
Cancilla et al., 2001, Fibroblast growth factor receptors and their ligands in the adult rat kidney., Kidney Int.
Launay et al., 1994, Comparative analysis of the tissue distribution of three fibroblast growth factor receptor mRNAs during amphibian morphogenesis., Differentiation
Beer et al., 2000, Fibroblast growth factor (FGF) receptor 1-IIIb is a naturally occurring functional receptor for FGFs that is preferentially expressed in the skin and the brain., J. Biol. Chem.
Mummery et al., 1993, Fibroblast growth factor-mediated growth regulation and receptor expression in embryonal carcinoma and embryonic stem cells and human germ cell tumours., Biochem. Biophys. Res. Commun.
Liu PCC et al., 2020, INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models., PLoS One
Wang et al., 2017, A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma., Eur. Urol.
Tabernero et al., 2015, Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors., J. Clin. Oncol.
Di Stefano et al., 2015, Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma., Clin. Cancer Res.
Patani et al., 2016, Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use., Oncotarget
Loriot Y et al., 2019, Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma., N Engl J Med
Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
Nishina T et al., 2018, Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors., Invest New Drugs
Davies et al., 2015, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors., Mol. Cancer Ther.
Capelletti et al., 2014, Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma., Clin. Cancer Res.
Gozgit et al., 2013, Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models., Cancer Chemother. Pharmacol.
Yang Z et al., 2018, Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy., EBioMedicine
Chandrani et al., 2017, Drug-sensitive FGFR3 mutations in lung adenocarcinoma., Ann. Oncol.
von Mässenhausen et al., 2016, Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma., Target Oncol
Singh et al., 2012, Transforming fusions of FGFR and TACC genes in human glioblastoma., Science
Liu et al., 2017, c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors., Clin. Cancer Res.
Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE
Guagnano et al., 2012, FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor., Cancer Discov
Pal SK et al., 2018, Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations., Cancer Discov
Nogova et al., 2017, Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study., J. Clin. Oncol.
Zhao et al., 2011, A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models., Mol. Cancer Ther.
Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
Watanabe Miyano et al., 2016, E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models., Mol. Cancer Ther.
St-Germain et al., 2009, Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition., Proc. Natl. Acad. Sci. U.S.A.
Manchado et al., 2016, A combinatorial strategy for treating KRAS-mutant lung cancer., Nature
Xie X et al., 2019, FGFR<sup>3S249C</sup> mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells., Exp Ther Med
Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
Sethakorn N et al., 2016, Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma., BJU Int
Wu et al., 2013, Identification of targetable FGFR gene fusions in diverse cancers., Cancer Discov
Deeks, 2012, Pazopanib: in advanced soft tissue sarcoma., Drugs
Matsui et al., 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition., Int. J. Cancer
Nakanishi et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol. Cancer Ther.
Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.
Guan et al., 2009, Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells., Anticancer Res.
Bodoor et al., 2010, FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population., Cancer Epidemiol
Qing et al., 2009, Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice., J. Clin. Invest.
Otsuka et al., 2011, Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy., Anticancer Res.
Chell et al., 2013, Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance., Oncogene
MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

VOFATAMAB FGFR3

Interaction Score: 1.78

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type multiple myeloma

Response Type sensitive

Approval Status Phase I

PMIDs:
None found

Sources:
JAX-CKB TTD
E-7090 FGFR3

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23175443 27535969 19901323

Sources:
JAX-CKB
PALIFERMIN FGFR3

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
11149756 11422746 7890137 10821861 7680555

Sources:
TEND TdgClinicalTrial DrugBank
LY-2874455 FGFR3

Interaction Score: 1.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
23175443 28034880 21900693

Sources:
JAX-CKB GuideToPharmacology ChemblInteractions
PEMIGATINIB FGFR3

Interaction Score: 0.89

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
32315352

Sources:
JAX-CKB DrugBank GuideToPharmacology
ERDAFITINIB FGFR3

Interaction Score: 0.82

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
26324363 25609060 26992226 31340094 28341788 28965185

Sources:
OncoKB PharmGKB JAX-CKB CIViC DrugBank GuideToPharmacology
INFIGRATINIB FGFR3

Interaction Score: 0.77

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
27998968 27053219 25294908 22837387 27401245 26270481 23002168 28034880 29848605 27870574 25589496

Sources:
CancerCommons MyCancerGenomeClinicalTrial OncoKB JAX-CKB CIViC TALC MyCancerGenome GuideToPharmacology ChemblInteractions
ROGARATINIB FGFR3

Interaction Score: 0.53

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
JAX-CKB GuideToPharmacology ChemblInteractions
FUTIBATINIB FGFR3

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
JAX-CKB GuideToPharmacology
DERAZANTINIB FGFR3

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology ChemblInteractions
BRIVANIB FGFR3

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
22238366 20124951

Sources:
PharmGKB JAX-CKB ChemblInteractions
NINTEDANIB FGFR3

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
22238366 18559524 31016670

Sources:
ClearityFoundationClinicalTrial JAX-CKB TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology
DEBIO-1347 FGFR3

Interaction Score: 0.36

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
OncoKB GuideToPharmacology
PONATINIB FGFR3

Interaction Score: 0.27

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Approval Status Preclinical - Cell line xenograft

Response Type predicted – sensitive

PMIDs:
22238366 25294908 28034880 23468082

Sources:
JAX-CKB CIViC DrugBank TALC MyCancerGenome
RO-4987655 FGFR3

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type bladder transitional cell papilloma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB
BRIVANIB ALANINATE FGFR3

Interaction Score: 0.25

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
None found

Sources:
TTD ChemblInteractions
TRAFERMIN FGFR3

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name trafermin, fibro/

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
AZD-4547 FGFR3

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
TRAPIDIL FGFR3

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
CAPIVASERTIB FGFR3

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
26351323

Sources:
JAX-CKB
MASITINIB FGFR3

Interaction Score: 0.19

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor 3 inhibitor

PMIDs:
None found

Sources:
MyCancerGenomeClinicalTrial MyCancerGenome ChemblInteractions
FP-1039 FGFR3

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name FP-1039

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
DOVITINIB FGFR3

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Indication/Tumor Type bladder urothelial carcinoma

Approval Status Preclinical - Cell culture

PMIDs:
22238366 23175443 24325461 27932416 28034880 21119661 25589496

Sources:
ClearityFoundationClinicalTrial CancerCommons DTC JAX-CKB TdgClinicalTrial CIViC TTD TALC MyCancerGenome GuideToPharmacology ChemblInteractions
ENMD-2076 FGFR3

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 3 inhibitor

Direct Interaction yes

Notes

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial TALC MyCancerGenome ChemblInteractions
AEE-788 FGFR3

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
LENVATINIB FGFR3

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17943726

Sources:
DrugBank
MK-2461 FGFR3

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
TTD GuideToPharmacology
PAZOPANIB FGFR3

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
27271022 23558953 23072642

Sources:
JAX-CKB CIViC DrugBank
CP-459632 FGFR3

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
XL-228 FGFR3

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome
RABEPRAZOLE SODIUM FGFR3

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
TTD MyCancerGenome
NINTEDANIB ESYLATE FGFR3

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions
BORTEZOMIB FGFR3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Clinical Status preclinical

Pathway activation

Variant Effect gain-of-function

PMIDs:
26619011 19331127 20542753 19381019 21273588 22869148 25157968

Sources:
DoCM CGI
ORANTINIB FGFR3

Interaction Score: 0.09

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
PAZOPANIB HYDROCHLORIDE FGFR3

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor 3 inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
XL-999 FGFR3

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CEDIRANIB FGFR3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type resistant

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
22238366 25589496

Sources:
DTC JAX-CKB
BUPARLISIB FGFR3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
28108151

Sources:
JAX-CKB
SELUMETINIB FGFR3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type urinary bladder cancer

Response Type no benefit

Approval Status Preclinical

PMIDs:
26438159

Sources:
JAX-CKB
TRAMETINIB FGFR3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung cancer

Response Type no benefit

Approval Status Preclinical

PMIDs:
27338794

Sources:
JAX-CKB
DACTOLISIB FGFR3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sorafenib + BEZ235

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

PMIDs:
26270481

Sources:
JAX-CKB
CHEMBL578061 FGFR3

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MLN-8054 FGFR3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ENMD-981693 FGFR3

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
SORAFENIB FGFR3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Sorafenib + BEZ235

Indication/Tumor Type urinary bladder cancer

Response Type sensitive

PMIDs:
26270481

Sources:
DTC JAX-CKB
ALPELISIB FGFR3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy BGJ398 + BYL719

Indication/Tumor Type transitional cell carcinoma

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
HESPERADIN FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
19035792

Sources:
DTC
GEMCITABINE FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29941343

Sources:
CIViC
ALISERTIB FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OSI-632 FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CISPLATIN FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31316618 29941343

Sources:
CIViC
ENTRECTINIB FGFR3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TOZASERTIB FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LINIFANIB FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DASATINIB FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
R-406 FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
RG-1530 FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SP-600125 FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CYC-116 FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TAE-684 FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
PF-00562271 FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
ILORASERTIB FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CENISERTIB FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FOSTAMATINIB FGFR3

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26516587

Sources:
DrugBank

Ensembl: ENSG00000068078
- Version: 101_38
Alternate Names:

FGFR3 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P22607
- Version: 01-August-2011
Alternate Names:

ENSG00000068078 Ensembl Gene Id

FGFR3_HUMAN Uniprot Id

2261 Entrez Gene Id

Gene Info:

Target Main Class Receptors

Target Subclass Kinase

Target Subclass FGFR

Publications:
TdgClinicalTrial: P22607
- Version: January-2014
Alternate Names:

FGFR3 Gene Symbol

Gene Info:

Target Class Receptors

Target Subclass EC:2.7.10.1

Publications:
RussLampel: ENSG00000068078
- Version: 26-July-2011
Alternate Names:

FGFR3 Display Id

ENSG00000068078 Ensembl Gene Id

FIBROBLAST GROWTH FACTOR RECEPTOR 3 PRECURSOR (EC 2.7.1.112) (FGFR-3). [SOURCE:UNIPROT/SWISSPROT;ACC:P22607] Description

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P22607
- Version: 11-September-2012
Alternate Names:

FGFR3 Uniprot Gene Name

FGFR3_HUMAN Uniprot Id

P22607 Uniprot Accession

Gene Info:

Uniprot Evidence 1: Evidence at protein level

Interpro Acc IPR001245

Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain

Gene Categories:

KINASE, DRUGGABLE GENOME

Publications:
CancerCommons: FGFR3
- Version: 25-July-2013
Alternate Names:

2261 Entrez Gene ID

Gene Info:

CancerCommons Reported Gene Name FGFRs

CancerCommons Reported Gene Name FGFR3 and others (VEGFR)

Publications:
GuideToPharmacology: 2261
- Version: 29-September-2020
Alternate Names:

3690 HUGO Gene ID

3690 HUGO Gene Symbol

fibroblast growth factor receptor 3 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name Type V RTKs: FGF (fibroblast growth factor) receptor family

GuideToPharmacology Gene Category ID 323

Publications:

JAX-CKB: FGFR3

Version: 27-September-2017

Alternate Names:

2261 CKB Entrez Id

FGFR3 CKB Gene Synonym

ACH CKB Gene Synonym

Gene Info:

Publications:

Gozgit et al., 2012, Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models., Mol. Cancer Ther.

Wang et al., 2017, A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma., Eur. Urol.

Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE

PharmGKB: FGFR3
- Version: 18-August-2020
Alternate Names:

PA28129 PharmGKB ID

Gene Info:

Publications:

Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics

CIViC: FGFR3

Version: 14-September-2020

Alternate Names:

2261 Entrez Gene ID

23 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE, CLINICALLY ACTIONABLE

Publications:

Chandrani et al., 2017, Drug-sensitive FGFR3 mutations in lung adenocarcinoma., Ann. Oncol.

Wu et al., 2013, Identification of targetable FGFR gene fusions in diverse cancers., Cancer Discov

Lamont et al., 2011, Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo., Br. J. Cancer

DrugBank: BE0002133

Version: 5.1.7

Alternate Names:

FGFR3 DrugBank Gene Name

P22607 UniProt Accession

2261 Entrez Gene Id

Gene Info:

Publications:

Gozgit et al., 2013, Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models., Cancer Chemother. Pharmacol.

Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.

Wind S et al., 2019, Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib., Clin Pharmacokinet

CGI: FGFR3

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Guan et al., 2009, Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells., Anticancer Res.

Otsuka et al., 2011, Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy., Anticancer Res.

DoCM: FGFR3

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Chang et al., 2016, Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity., Nat. Biotechnol.

Guan et al., 2009, Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells., Anticancer Res.

Bodoor et al., 2010, FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population., Cancer Epidemiol

DTC: FGFR3
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Bamborough et al., 2008, Assessment of chemical coverage of kinome space and its implications for kinase drug discovery., J. Med. Chem.
HingoraniCasas: ENSG00000068078
- Version: 31-May-2017
Alternate Names:

ENSG00000068078 Gene Symbol

FGFR3 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TALC: FGFR-3
- Version: 12-May-2016
Alternate Names:

FGFR-3 Gene Symbol

Gene Info:

Publications:
ChemblInteractions: JTK4
- Version: chembl_23
Alternate Names:

JTK4 GENE_SYMBOL

FGFR3 GENE_SYMBOL

Fibroblast growth factor receptor 3 UNIPROT

Gene Info:

Publications:
MyCancerGenome: FGFR3
- Version: 20-Jun-2017
Alternate Names:

2261 Entrez Gene Id

FGFR3 MyCancerGenome Gene Symbol

FGFR1-3 MyCancerGenome Reported Gene Name

Gene Info:

Publications:
TALC: FGFR3
- Version: 12-May-2016
Alternate Names:

FGFR3 Gene Symbol

Gene Info:

Publications:
OncoKB: FGFR3
- Version: 23-July-2020
Alternate Names:

2261 OncoKB Entrez Id

JTK4 OncoKB Gene Synonym

HSFGFR3EX OncoKB Gene Synonym

Gene Info:

Publications:
Pharos: FGFR3
- Version: 03-September-2020
Alternate Names:

Fibroblast growth factor receptor 3 Gene Name

P22607 UniProt ID

Gene Info:

Gene Categories:

KINASE

Publications:
GO: FGFR3
- Version: 05-September-2020
Alternate Names:

JTK4 GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE, TYROSINE KINASE

Publications:
Tempus: FGFR3
- Version: 11-November-2018
Alternate Names:

FGFR3 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
dGene: FGFR3
- Version: 27-Jun-2013
Alternate Names:

2261 Gene ID

ACH dGene Synonym

CD333 dGene Synonym

Gene Info:

Gene Categories:

KINASE, TYROSINE KINASE

Publications:
TTD: Fibroblast growth factor receptor 3
- Version: 2020.06.01
Alternate Names:

FGFR3 TTD Gene Abbreviation

T91331 TTD Target ID

Gene Info:

Publications:
ClearityFoundationClinicalTrial: FGFR3
- Version: 15-June-2013
Alternate Names:

Gene Info:

Publications:
MyCancerGenomeClinicalTrial: FGFR3
- Version: 30-February-2014
Alternate Names:

Gene Info:

Publications:
MskImpact: FGFR3
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: FGFR3
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: FGFR3
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: FGFR3
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Indication/Tumor Type	multiple myeloma
Response Type	sensitive
Approval Status	Phase I

Indication/Tumor Type	breast carcinoma
Response Type	sensitive
Approval Status	Preclinical

Trial Name	rHu-KGF, keratinocyte growth factor (KGF),Kepivance
Novel drug target	Established target

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Notes
Mechanism of Interaction	Fibroblast growth factor receptor inhibitor
Direct Interaction	yes

Response Type	resistant
Indication/Tumor Type	urinary bladder cancer
Evidence Type	Actionable

Indication/Tumor Type	bladder transitional cell papilloma
Response Type	no benefit
Approval Status	Preclinical - Cell culture

Trial Name	trafermin, fibro/
Novel drug target	Established target

Direct Interaction	yes
Mechanism of Interaction	Fibroblast growth factor receptor 3 inhibitor

Notes
Indication/Tumor Type	bladder urothelial carcinoma
Approval Status	Preclinical - Cell culture

Clinical Status	preclinical
Pathway	activation
Variant Effect	gain-of-function

Indication/Tumor Type	lung cancer
Response Type	no benefit
Approval Status	Preclinical

combination therapy	Sorafenib + BEZ235
Indication/Tumor Type	urinary bladder cancer
Response Type	sensitive

combination therapy	BGJ398 + BYL719
Indication/Tumor Type	transitional cell carcinoma
Response Type	predicted – sensitive

ENSG00000068078	Ensembl Gene Id
FGFR3_HUMAN	Uniprot Id
2261	Entrez Gene Id

FGFR3	Display Id
ENSG00000068078	Ensembl Gene Id
FIBROBLAST GROWTH FACTOR RECEPTOR 3 PRECURSOR (EC 2.7.1.112) (FGFR-3). [SOURCE:UNIPROT/SWISSPROT;ACC:P22607]	Description

FGFR3	Uniprot Gene Name
FGFR3_HUMAN	Uniprot Id
P22607	Uniprot Accession

3690	HUGO Gene ID
3690	HUGO Gene Symbol
fibroblast growth factor receptor 3	HUGO Gene Name

FGFR3 Gene Record

FGFR3 2261 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type multiple myeloma Response Type sensitive Approval Status Phase I

PMIDs: None found

Sources: JAX-CKB TTD

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type breast carcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 23175443 27535969 19901323

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance Novel drug target Established target

PMIDs: 11149756 11422746 7890137 10821861 7680555

Sources: TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical

PMIDs: 23175443 28034880 21900693

Sources: JAX-CKB GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 32315352

Sources: JAX-CKB DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: 26324363 25609060 26992226 31340094 28341788 28965185

Sources: OncoKB PharmGKB JAX-CKB CIViC DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Mechanism of Interaction Fibroblast growth factor receptor inhibitor Direct Interaction yes

PMIDs: 27998968 27053219 25294908 22837387 27401245 26270481 23002168 28034880 29848605 27870574 25589496

Sources: CancerCommons MyCancerGenomeClinicalTrial OncoKB JAX-CKB CIViC TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: JAX-CKB GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: JAX-CKB GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Fibroblast growth factor receptor inhibitor Direct Interaction yes Indication/Tumor Type Advanced Solid Tumor

PMIDs: 22238366 20124951

Sources: PharmGKB JAX-CKB ChemblInteractions

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type resistant Indication/Tumor Type urinary bladder cancer Evidence Type Actionable

PMIDs: 22238366 18559524 31016670

Sources: ClearityFoundationClinicalTrial JAX-CKB TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: OncoKB GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Response Type resistant Approval Status Preclinical - Cell line xenograft Response Type predicted – sensitive

PMIDs: 22238366 25294908 28034880 23468082

Sources: JAX-CKB CIViC DrugBank TALC MyCancerGenome

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type bladder transitional cell papilloma Response Type no benefit Approval Status Preclinical - Cell culture

PMIDs: 26438159

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs: None found

Sources: TTD ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info: Trial Name trafermin, fibro/ Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type multiple myeloma

Response Type sensitive

Approval Status Phase I

PMIDs:
None found

Sources:
JAX-CKB TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast carcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23175443 27535969 19901323

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name rHu-KGF, keratinocyte growth factor (KGF),Kepivance

Novel drug target Established target

PMIDs:
11149756 11422746 7890137 10821861 7680555

Sources:
TEND TdgClinicalTrial DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
23175443 28034880 21900693

Sources:
JAX-CKB GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
32315352

Sources:
JAX-CKB DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
26324363 25609060 26992226 31340094 28341788 28965185

Sources:
OncoKB PharmGKB JAX-CKB CIViC DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

PMIDs:
27998968 27053219 25294908 22837387 27401245 26270481 23002168 28034880 29848605 27870574 25589496

Sources:
CancerCommons MyCancerGenomeClinicalTrial OncoKB JAX-CKB CIViC TALC MyCancerGenome GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
JAX-CKB GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
JAX-CKB GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

Direct Interaction yes

Indication/Tumor Type Advanced Solid Tumor

PMIDs:
22238366 20124951

Sources:
PharmGKB JAX-CKB ChemblInteractions

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Indication/Tumor Type urinary bladder cancer

Evidence Type Actionable

PMIDs:
22238366 18559524 31016670

Sources:
ClearityFoundationClinicalTrial JAX-CKB TdgClinicalTrial DrugBank TALC MyCancerGenome GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
OncoKB GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Response Type resistant

Approval Status Preclinical - Cell line xenograft

Response Type predicted – sensitive

PMIDs:
22238366 25294908 28034880 23468082

Sources:
JAX-CKB CIViC DrugBank TALC MyCancerGenome

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type bladder transitional cell papilloma

Response Type no benefit

Approval Status Preclinical - Cell culture

PMIDs:
26438159

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
None found

Sources:
TTD ChemblInteractions

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name trafermin, fibro/

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Fibroblast growth factor receptor inhibitor

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
26351323

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

FGFR3	DrugBank Gene Name
P22607	UniProt Accession
2261	Entrez Gene Id

JTK4	GENE_SYMBOL
FGFR3	GENE_SYMBOL
Fibroblast growth factor receptor 3	UNIPROT

2261	OncoKB Entrez Id
JTK4	OncoKB Gene Synonym
HSFGFR3EX	OncoKB Gene Synonym

Fibroblast growth factor receptor 3	Gene Name
P22607	UniProt ID